natgillin/translations-raw huggingface dataset:
This messenger is involved in causing inflammation and is found at high levels in patients with the diseases that Simponi is used to treat.
Ta prenašalec sodeluje pri povzročanju vnetja in je prisoten v visokih koncentracijah pri bolnikih z boleznimi, ki se zdravijo z zdravilom Simponi.
This messenger is involved in causing inflammation and is found in high levels in patients with CAPS, Still’s disease and gouty arthritis.
Ta sodeluje pri povzročitvi vnetja in je v velikih količinah prisotna pri bolnikih z obolenji CAPS, Stillovo boleznijo ali protinskim artritisom.
This messenger is produced in high levels in patients with rheumatoid arthritis, causing inflammation of the joints and joint damage, and is also involved in the inflammation associated with CAPS.
Ta prenašalec pri bolnikih z revmatoidnih artritisom nastaja v velikih količinah, kar povzroča vnetje in poškodbe sklepov, vpletena pa je tudi v proces vnetja, značilnega za s kriopirinom povezane sindrome.
This metabolite is responsible for essentially all the in vivo activity of Arava.
Ta je odgovoren za praktično vso aktivnost zdravila Arava in- vivo.
This metabolite is responsible for essentially all the in vivo activity of Leflunomide Winthrop.
Ta je odgovoren za praktično vso aktivnost zdravila Leflunomid Winthrop in vivo.
This metabolite is responsible for essentially all the in vivo activity of Leflunomide Winthrop.
Ta je odgovoren za praktično vso aktivnost zdravila Leflunomid Winthrop in- vivo.
This metabolite is responsible for essentially all the in vivo activity of leflunomide.
Ta je odgovoren za praktično vso aktivnost zdravila Leflunomid Teva in vivo.
This method is recommended when assessing patients’ CrCL prior to and during Lixiana treatment.
Ta metoda je priporočena pri ocenjevanju CrCL bolnikov pred zdravljenjem z zdravilom Lixiana in med njim.
This method is recommended when assessing patients’ CrCL prior to and during Pradaxa treatment.
To je priporočena metoda za ocenjevanje CrCl pred zdravljenjem z zdravilom Pradaxa in med njim.
This method of treatment involves applying a brief illumination from a strong red light source designed for this purpose.
Ta oblika zdravljenja vključuje uporabo kratke osvetlitve z močnim rdečim svetlobnim virom, zasnovanim za ta namen.
This might happen:
To se lahko zgodi, ce:
This minimum distribution rate is:
Minimalna gostota polaganja je:
This multi-centre trial was conducted in patients with metastatic breast cancer, who were treated every 3 weeks with single-agent paclitaxel, either as solvent-based paclitaxel 175 mg/m2 given as a 3-hour infusion with premedication to prevent hypersensitivity (N = 225), or as Abraxane 260 mg/m2 given as a 30 minute infusion without premedication (N = 229).
To raziskavo so izvedli v več centrih pri bolnikih z metastatskim rakom dojk, ki so vsake 3 tedne prejemali paklitaksel kot samostojno zdravilo, ali kot paklitaksel na bazi topila v odmerku 175 mg/m2 v obliki 3-urne infuzije s premedikacijo za preprečitev preobčutljivosti (N = 225) ali pa kot zdravilo Abraxane v odmerku 260 mg/m2 v obliki 30-minutne infuzije brez premedikacije (N = 229).
This multidose preparation can be used for several patients over a period of 1 month after reconstitution.
Ta večodmerni pripravek lahko uporabimo za več bolnikov v času 1 meseca po pripravi.
This multipack is not intended to be supplied directly to the animal owner. (for 5 x 1, 10 x 1 and 20 x 1 multipacks only)
To skupno pakiranje ni namenjeno oskrbi neposredno imetniku živali. (samo za skupna pakiranja 5 x 1, 10 x 1 in 20 x 1)
This must be done even if the patient has already been taking another medicine containing fentanyl, because fentanyl from different medicines may not absorbed into the blood at the same speed.
To velja tudi v primeru, če bolnik že jemlje drugo zdravilo, ki vsebuje fentanil, saj se ta iz drugih zdravil v kri ne absorbira enako hitro.
This must be investigated by your doctor. if you have active uterine cancer.
Tako krvavitev mora raziskati vaš zdravnik. če imate aktivnega raka maternice.
This mutation affects the gene for a protein called cystic fibrosis transmembrane conductance regulator (CFTR) which is involved in regulating the production of mucus and digestive juices.
Ta mutacija prizadene gen za beljakovino, imenovano transmembranski regulator cistične fibroze (CFTR), ki sodeluje pri uravnavanju nastajanja sluzi in prebavnih sokov.
This mutation in the gene may have caused the melanoma to develop.
Ta mutacija gena je morda povzročila nastanek melanoma.
This nebuliser monitors the breathing pattern to determine the aerosol pulse time required to deliver the pre-set dose of 2.5 or 5 microgram iloprost.
Nebulator spremlja način dihanja in tako določi pulzni čas aerosola, ki je potreben za dovajanje predhodno nastavljenega odmerka 2,5 ali 5 mikrogramov iloprosta.
This nebuliser monitors the breathing pattern to determine the aerosol pulse time required to deliver the pre-set dose of 2.5 or 5 microgram iloprost.
Nebulator spremlja način dihanja in tako določi pulzni čas aerosola, potreben za dovajanje nastavljenega odmerka 2,5 ali 5 miligramov iloprosta.
This nebuliser monitors the breathing pattern to determine the aerosol pulse time required to deliver the pre-set dose of 5 micrograms iloprost of the Ventavis 20 microgram/ml nebuliser solution (1 ml ampoule with yellow and red rings).
Nebulator spremlja način dihanja in tako določi pulzni čas aerosola, potreben za dovajanje nastavljenega odmerka 5 mikrogramov iloprosta zdravila Ventavis 20 mikrogramov/ml inhalacijska raztopina za nebulator (1-mililitrska ampula z rumenim in rdečim obročem).
This non-target specific efflux mechanism has also been demonstrated to reduce the in vitro activity of streptogramin A.
Dokazano je bilo, da ta ciljno nespecifični mehanizem prenosa zmanjša tudi in vitro aktivnost streptogramina A.
This normalises the transport of ions through channels making the secretions less thick.
Tako se prenos ionov skozi kanalčke normalizira in izločki postanejo manj gosti.
This normalises the transport of ions through channels, making the secretions less thick and thereby relieving symptoms of the disease.
To normalizira prehod ionov skozi kanalčke, kar pomeni, da so izločki manj gosti, s tem pa se olajšajo simptomi bolezni.
This normally gets better after a few days.
Običajno te težave hitro minejo.
This observation with trivalent Fluenz is relevant to the use of Fluenz Tetra because Fluenz Tetra (influenza vaccine -live attenuated, nasal) is identical to Fluenz with the only difference being the addition of a fourth strain (a second B strain) to Fluenz Tetra.
Ta sprememba pri trivalentnem cepivu Fluenz je pomembna za uporabo cepiva Fluenz Tetra, saj je Fluenz Tetra (cepivo proti gripi – z živimi oslabljenimi virusi, nosno) identično cepivu Fluenz, pri čemer je edina razlika dodatek četrtega seva (drugi B sev) v cepivu Fluenz Tetra.
This occurred 2-24 hours after administration of idarucizumab mainly at timepoints ≥12 hours.
Do tega je prišlo 2 do 24 ur po dajanju idarucizumaba zlasti ob času ≥ 12 ur.
This occurs when the needle starts retracting in about
Do tega pride, ko se igla začne umikati, po približno 5
This OptiSet must not be used.
Bolnik ne sme uporabljati tega OptiSeta.
This OptiSet must not be used.
Ne uporabljajte tega OptiSeta.
This overfill ensures that after dilution with the entire contents of the accompanying solvent for TAXOTERE vial, there is a minimal extractable premix volume of 2 ml containing 10 mg/ml docetaxel which corresponds to the labelled amount of 20 mg/0.5 ml per vial.
Po razredčenju s celotno vsebino spremljajoče viale z vehiklom za zdravilo TAXOTERE to prepolnjenje zagotavlja, da je mogoče izvleči najmanj 2 ml osnovne raztopine z 10 mg/ml docetaksela, kar ustreza označeni količini 20 mg na vialo.
This overfill ensures that after dilution with the entire contents of the accompanying solvent for TAXOTERE vial, there is a minimal extractable premix volume of 8 ml containing 10 mg/ml docetaxel which corresponds to the labelled amount of 80 mg/2 ml per vial.
Po razredčenju s celotno vsebino spremljajoče viale z vehiklom za zdravilo TAXOTERE to prepolnjenje zagotavlja, da je mogoče izvleči najmanj 8 ml osnovne raztopine z 10 mg/ml docetaksela, kar ustreza označeni količini 80 mg na vialo.
This pack (treatment initiation pack) is used when you start your treatment with Vimpat.
To pakiranje (paket za začetek zdravljenja) se uporablja, ko začenjate zdravljenje z zdravilom Vimpat.
This pack aims to inform them about the risks and treatment recommendations with Exjade, including choosing the right dose, that the doses are different for the film-coated tablets and dispersible tablets, and the need to monitor the patient’s health, especially kidney function.
Namen tega gradiva je seznaniti jih s tveganji in priporočili v zvezi z zdravilom Exjade, vključno z izbiro ustreznega odmerka, s tem, da so odmerki za filmsko obložene tablete in disperzibilne tablete različni in da je treba spremljati bolnikovo zdravje, zlasti delovanje ledvic.
This pack also contains one Zirela Nebuliser Handset.
To pakiranje vsebuje tudi en nebulator Zirela.
This package meets the patient’s needs for the first 12 injections.
Ta pakiranja zadostujejo za potrebe bolnika za prvih 12 injekcij.
This pain reduction persisted through 4 years of Replagal therapy in 9 patients (in patients 7 – 18 years of age).
To zmanjšanje bolečine je pri 9 bolnikih trajalo 4 leta zdravljenja z zdravilom Replagal (pri bolnikih 7 – 18 let).
This particularity will increase the ratio between the desired local anti- inflammatory effect in the skin and the undesirable systemic effects.
Ta posebnost poveča razmerje med želenim lokalnim protivnetnim učinkom v koži in neželenimi sistemskimi učinki.
This particularly happens in patients whose kidneys are not working properly.
Pojavi se zlasti pri bolnikih, ki jim ledvice ne delujejo pravilno.
This particularly includes the following situations with increased bleeding risk:
To velja še zlasti za naslednja stanja s povečanim tveganjem krvavitve:
This patient alert card contains important safety information that you need to be aware of before and during treatment with Simponi.
Ta opozorilna kartica vsebuje pomembne varnostne podatke, ki jih morate upoštevati pred in med zdravljenjem z zdravilom Simponi.
This patient is using eliglustat (Cerdelga) for the treatment of Gaucher Disease type 1.
Ta bolnik uporablja eliglustat (zdravilo Cerdelga) za zdravljenje Gaucherjeve bolezni tipa 1.
This patient received 0.3 mg of Thyrogen as a single intravenous (IV) bolus and, 15 minutes later experienced severe nausea, vomiting, diaphoresis, hypotension and tachycardia.
Pri tem bolniku, ki je dobil enkraten intravenski (i.v.) bolus 0,3 mg zdravila Thyrogen, so se po 15 minutah pojavili naslednji neželeni učinki: huda navzea, bruhanje, čezmerno znojenje, hipotenzija in tahikardija.
This patient recovered within the 60-day follow-up period.
Ta bolnik je v 60- dnevnem obdobju spremljanja okreval.
This patient, however, was also receiving concomitant whole brain irradiation and had previously received intraventricular methotrexate.
Vendar so temu bolniku hkrati obsevali tudi celotne možgane, pred tem pa je intraventrikularno prejel že metotreksat.
This pattern of treatments will normally be repeated every three weeks, for all cancers.
Pri vseh oblikah raka se opisani vzorec zdravljenja običajno ponovi vsake tri tedne.
This pen can only be used for one single injection, and must be thrown away after use.
Peresnik je mogoče uporabiti le za eno injiciranje in ga je treba po uporabi zavreči.
This pen has been designed to deliver the dose that is shown in the window.
Ta injekcijski peresnik je bil zasnovan za dovajanje odmerka, prikazanega v okencu.
This pen is for single use only.
Ta injekcijski peresnik je samo za enkratno uporabo.
This pen is not recommended for use by people who are blind or who cannot see well enough.
Tega injekcijskega peresnika ne priporočamo uporabljati slepim ali osebam, ki ne vidijo dovolj dobro.
This pen is not recommended for use by the blind or visually impaired persons without the assistance of a person trained in the proper use of the product.
Uporabo tega peresnika ne priporočamo slepim ali slabovidnim osebam, ki so brez pomoči osebe, usposobljene za pravilno uporabo izdelka.
This Pen is not recommended for use by the blind or visually impaired without the help of someone trained to use the Pen.
Ne priporočamo uporabe tega peresnika slepim ali slabovidnim osebam brez pomoči osebe, ki je usposobljena za uporabo peresnika.
This pen is only for one person.
Ta peresnik je namenjen le za uporabo pri eni sami osebi.
This pen is only for the patients use.
Ta injekcijski peresnik mora uporabljati samo bolnik.
This pen is only for the patients use.
Ta injekcijski peresnik uporabljajte le vi sami.
This pen is only for you.
Ta peresnik je namenjen le za vašo uporabo.
This pen is only for your use.
Ta injekcijski peresnik uporabljajte samo vi.
This percentage may vary according to ethnic background.
Ta odstotek se lahko razlikuje glede na etnično pripadnost.
This percentage was lower for children aged 2 to 4 years, with around 57% of them being free of disease flares after 24 weeks.
Odstotek je bil nižji pri otrocih, starih od 2 do 4 let, saj pri 57 % po 24 tednih ni prišlo do ponovnega zagona bolezni.
This period depends on the breed.
Pri psih je obdobje rasti pri različnih pasmah različno.
This phase III clinical trial compared rituximab/cyclophosphamide/doxorubicin/vincristine/prednisone (R-CHOP) plus bevacizumab to R- CHOP without bevacizumab.
V kliničnem preskušanju faze III so primerjali shemo rituksimab/ciklofosfamid/doksorubicin/vinkristin/prednizon (R-CHOP) in bevacizumab s shemo R-CHOP brez bevacizumaba.
This phase looked at the long-term effect on platelet levels.
V tej fazi so proučevali dolgoročne učinke na ravni trombocitov.
This phase of elimination is slow, resulting in a median terminal elimination half-life t1/2 of approximately 22 hours following buccal administration of the effervescent formulation and approximately 18 hours following intravenous administration.
Ta faza izločanja je počasna, kar ima za posledico mediano končno razpolovno dobo izločanja t1/2 približno 22 ur po bukalni aplikaciji efervescentne formulacije in približno 18 ur po intravenski aplikaciji.
This phosphate-buffered soluble insulin is intended for continuous subcutaneous insulin infusion (CSII) in external insulin infusion pumps.
S fosfatom pufrani topni insulin je namenjen za stalno subkutano infuzijo insulina v zunanjih insulinskih infuzijskih crpalkah.
This plasma concentration was observed in a child with a secondary infected dermatosis, for which retapamulin is not indicated for use.
To koncentracijo v plazmi so izmerili pri otroku s sekundarno okuženo dermatozo, pri katerih uporaba retapamulina ni indicirana.
This population primarily consisted of children with minimal hepatitis B. A dose of 3 mg/kg once daily (up to a maximum of 100 mg daily) was used in children aged 2 to 11 years and a dose of 100 mg once daily in adolescents aged 12 years and above.
Populacijo so v glavnem sestavljali otroci z minimalnim hepatitisom B. Otroci, stari od 2 do 11 let, so jemali odmerek 3 mg/kg enkrat dnevno (do največjega odmerka 100 mg dnevno), mladostniki, stari 12 let in več, pa so jemali odmerek 100 mg enkrat dnevno.
This potential difference is sufficiently small to draw an overall conclusion of non- inferiority of abacavir once daily over abacavir twice daily.
Ta možna razlika je dovolj majhna, da lahko postavimo končen zaključek, da sta si režima odmerjanja abakavirja enkrat ali dvakrat na dan enakovredna.
This potentially may have clinical significance in patients with pre-existing arrhythmias or cardiac conduction disorders or patients who are being treated with antiarrhythmics or beta- blockers.
To bi lahko bilo klinično pomembno pri bolnikih z že obstoječimi aritmijami ali motnjami srčne prevodnosti ali pri bolnikih, ki se zdravijo z antiaritmiki ali blokatorji adrenergičnih receptorjev beta.
This pressure reduces the amount of oxygen that can get into the blood in the lungs, making physical activity more difficult.
Povečani tlak zniža količino kisika, ki lahko pride v kri v pljučih, zaradi česar je telesna dejavnost otežena.
This pressure reduces the amount of oxygen that can get into the blood in the lungs, making physical activity more difficult.
Zaradi visokega tlaka se zmanjša količina kisika, ki prehaja v kri v pljučih, kar oteži izvajanje telesnih dejavnosti.
This prevents infestation of the environment of the treated animal with the developing flea stages.
To prepreči okužbo okolja zdravljene živali z razvojnimi oblikami bolh.
This problem could be exacerbated by coadministration with active substances that inhibit TPMT, such as olsalazine, mesalazine or sulfasalazine.
Sočasna uporaba zdravilnih učinkovin, ki zavirajo TPMT, kot so olsalazin, mesalazin ali sulfasalazin, lahko to težavo še poslabša.
This procedure describes the preparation of a 6 mg/ml suspension that will provide one patient with enough medication for a 5-day course of treatment or a 10-day course of prophylaxis.
Postopek opisuje pripravo 6 mg/ml suspenzije, ki enemu bolniku zadošča za 5 dnevni potek zdravljenja ali 10 dnevni potek preprečevanja bolezni.
This procedure describes the preparation of a 6 mg/ml suspension that will provide one patient with enough medicine for a 5-day course of treatment or a 10-day course of prophylaxis.
Postopek opisuje pripravo 6 mg/ml suspenzije, ki bo enemu bolniku zadoščala za 5 dnevni potek zdravljenja ali 10 dnevni potek preprečevanja bolezni.
This procedure will also be performed if you are under 12 years of age and have unexplained blood in your bowel movements (stools).
Ta postopek bo potreben tudi, če ste mlajši od 12 let in imate nepojasnjeno kri v blatu.
This process is influenced by several factors (e.g. insulin dosage, injection route and site, thickness of subcutaneous fat, type of diabetes).
Na to dogajanje vpliva vec dejavnikov (npr. odmerjanje insulina, nacin in mesto injiciranja, debelina podkožnega mašcevja, tip diabetesa).
This produces the symptoms of the disease: anaemia (low red blood cell counts), tiredness, easy bruising and a tendency to bleed, an enlarged spleen and liver, and bone pain and breaks.
To povzroča simptome bolezni: anemijo (nizko število rdečih krvničk), utrujenost, nagnjenost k podplutbam in krvavitvam, povečano vranico in jetra ter bolečine v kosteh in zlome.
This product also contains sugar, preservatives: methyl parahydroxybenzoate and propyl parahydroxybenzoate
To zdravilo vsebuje tudi sladkor in konzervanse: metilparahidroksibenzoat in propilparahidroksibenzoat.
This product and the wet skin of a recently treated animal may be slightly irritating to skin and/or eyes.
To zdravilo in vlažna koža pravkar zdravljene živali lahko rahlo dražita kožo in/ali oči.
This product can increase plasma concentrations of concomitantly administered medicinal products that are metabolized via CYP3A4.
To zdravilo lahko zviša plazemske koncentracije sočasno uporabljenih zdravil, ki se presnavljajo prek CYP3A4.
This product contains 48 vol % ethanol (alcohol), i.e up to 4.2 g per dose, equivalent to 84 ml of beer, 35 ml wine per dose.
To zdravilo vsebuje 48 vol % etanola (alkohola), to je do 4,2 g na odmerek, kar ustreza 84 ml piva, 35 ml vina na odmerek.
This product contains aspartame.
To zdravilo vsebuje aspartam.
This product contains indoxacarb and permethrin.
To zdravilo vsebuje indoksakarb in permetrin.
This product contains indoxacarb.
To zdravilo vsebuje indoksakarb.
This product contains lactose monohydrate: See package leaflet for further information
To zdravilo vsebuje laktozo monohidrat: za nadaljnje informacije glejte navodilo za uporabo.
This product contains sucrose 1073 mg (see section 4.4).
Cepivo vsebuje 1.073 mg saharoze (glejte poglavje 4.4).
This product does not require any special storage conditions.
Za shranjevanje zdravila niso potrebna posebna navodila.
This product for dogs should not be used in cats due to the different dosing devices.
Tega zdravila za pse ne smemo uporabljati pri mačkah, ker za to živalsko vrsto ni primerno.
This product is for hospital use only.
Zdravilo je namenjeno le bolnišnični uporabi.
This product is only for use in horses weighing between 500 and 600 kg.
Ta izdelek je samo za uporabo pri konjih, ki tehtajo med 500 in 600 kg.
This product is preservative free and therefore the prepared dosing solution should be used immediately.
Ker zdravilo ne vsebuje konzervansov, je treba pripravljeno raztopino, pripravljeno za uporabo, nemudoma uporabiti.
This product is to be administered only once within a 24 hour period.
To zdravilo se lahko uporabi samo enkrat v 24-urnem obdobju.
This product may be toxic to humans after ingestion.
To zdravilo za uporabo v veterinarski medicini je lahko toksično za ljudi po zaužitju.
This product may cause gastrointestinal disturbances if ingested.
Zdravilo lahko povzroči gastrointestinalne težave pri zaužitju.
This product may cause gastrointestinal disturbances if ingested.
Če se zdravilo zaužije, lahko povzroči gastrointestinalne težave.
This product may contain antibodies against BVD virus.
Zdravilo lahko vsebuje protitelesa proti virusu goveje virusne diareje (BVD).
This product reduced in clinical trials pain and inflammation in cats and dogs undergoing orthopaedic or soft tissue surgery.
To zdravilo je v kliničnih poskusih zmanjšalo bolečino in vnetje pri mačkah in psih, podvrženih ortopedskim operativnim posegom ali operativnim posegom na mehkih tkivih.
This product reduced in clinical trials the lameness and inflammation of dogs with chronic osteoarthritis.
To zdravilo je v kliničnih študijah zmanjšalo šepanje in vnetje pri psih s kroničnim osteoartritisom.
This product should be used with caution in patients receiving concomitant orally administered active substances that are metabolised primarily through CYP3A4 and with a narrow therapeutic range, such as cyclosporine, tacrolimus, sirolimus, everolimus, alfentanil, diergotamine, ergotamine, fentanyl, and quinidine (see section 4.5).
To zdravilo je treba uporabljati previdno pri bolnikih, ki sočasno peroralno prejemajo zdravilne učinkovine, ki se primarno presnavljajo prek CYP3A4 in imajo ozko terapevtsko območje, kot so ciklosporin, takrolimus, sirolimus, everolimus, alfentanil, diergotamin, ergotamin, fentanil in kinidin (glejte poglavje 4.5).
This product should not be used to prevent nausea and vomiting in the days following chemotherapy if not associated with another chemotherapy administration.
Tega zdravila ne smemo uporabljati za preprečevanje navzee in bruhanja v dneh po kemoterapiji, razen v povezavi z dajanjem naslednjega cikla kemoterapije.
This product should only be administered by a veterinary surgeon.
To zdravilo lahko daje samo veterinar.
This product should only be used in conjunction with a behaviour modification programme recommended by your veterinary surgeon.
Izdelek se uporablja samo v kombinaciji s tehnikami za spremembo vedenja, ki jo predlaga vaš veterinar.
This product should therefore only be used during pregnancy and lactation according to the benefit-risk assessment by the responsible veterinarian.
Zato se sme v obdobju brejosti ali laktacije to zdravilo uporabljati samo skladno z oceno razmerja med koristmi in tveganji, ki jo opravi odgovorni veterinar.
This product will only be handled and given to you by people who are trained and qualified to use it safely.
Z zdravilom bodo ravnali in vam ga dajali le strokovnjaki, usposobljeni za njegovo varno uporabo.
This profile is consistent whether summarising all early studies (n=248) or only those studies in osteosarcoma (n=51).
Ta profil je skladen s povzetkom vseh zgodnjih študij (n=248) ali samo študij o osteosarkomu (n=51).
This programme shall ensure that physicians who intend to prescribe Humira are aware of:
Ta program mora zagotoviti, da se zdravniki, ki nameravajo predpisovati zdravilo Humira, zavedajo:
This prolongation increases slowly over time in the first 6-10 weeks of treatment and remains stable therafter.
To podaljšanje se sčasoma počasi povečuje prvih 6–10 tednov zdravljenja, nato pa se stabilizira.